- Exhibit & Support
- Hotel & Travel
Two new therapies gained FDA approval a year ago: Luthathera™[Lutetium-177 Dotatate] and Azedra™[I-131 Iobenguane]. Luthathera™ is the first radioactive drug approved to treat adult patients with advanced neuroendocrine tumors that affect the pancreas or gastrointestinal tract. Azedra™ is the first approved treatment for MIBG-avid malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma. Hear two leading physicians from the University of Texas MD Anderson Cancer Center share their largely positive experiences with the new therapies.
At the completion of this application-based activity, participants will be able to:
This activity is approved for Board Certified Nuclear Pharmacist (BCNP) recertification credits.